Kalvista Pharmaceuticals Inc (KALV NASDAQ) stock market data APIs
$11.4815
-0.28(-2.4%)
as of July 1, 2025
Try our APIs with
free plan!
Kalvista Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Prev. Close
11.4815
Open
11.2062
High
11.8486
Low
11.1245
52 wk Range
7.3-15.5
Market Cap
562 M
Shares Outstanding
49 716 K
Revenue
3 824 K
EPS
-0.92
Beta
-0.021
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kalvista Pharmaceuticals Inc data using free add-ons & libraries
Get Kalvista Pharmaceuticals Inc Fundamental Data
Kalvista Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 3 824 K
- EBITDA: -180 520 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-10
- EPS/Forecast: -0.8678
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kalvista Pharmaceuticals Inc News
New
KalVista grants Pendopharm exclusive rights for sebetralstat in Canada
CAMBRIDGE, Mass. - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a $580 million market cap biotech company whose shares have gained nearly 38% year-to-date, announced Wednesday that its subsidiary has...
FDA's Makary sought to reject KalVista’s drug: report
[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images FDA Commissioner Marty Makary reportedly initiated a brief request last week to decline approva...
Stocks Rally as Iran Signals it Wants an End to Hostilities
The S&P 500 Index ($SPX) (SPY) is up +1.15%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +1.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.49%. June E-mini S&P futures (ESM25) are u...
Stocks Rebound on Hopes Israel-Iran Conflict Will be Contained
The S&P 500 Index ($SPX) (SPY) is up +0.79%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.73%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.98%. June E-mini S&P futures (ESM25) are u...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
